Curasight A/S resolves to issue a convertible loan note

Curasight's board, following authorization at an extraordinary general meeting, has resolved to issue a convertible loan note to Fenja Capital: the facility comprises a DKK25m first tranche (DKK10m refinancing of an existing loan and DKK15m new disbursement) and an additional DKK15m tranche available in Q2 2026 (total facility DKK40m, convertible portion DKK25m). Terms include a 5% setup fee, interest of 1.25% per started 30-day period on drawn amounts (0.4% on undrawn), maturity 29-Dec-2026, conversion at 125% of the directed-issue subscription price and issuance of up to 2,506,266 new shares (~4.97% dilution); Sedermera and DLA Piper act as advisors.

Analysis

Market structure: The financing injects up to DKK 25m with DKK 15m effective immediately and optional DKK 15m in Q2 2026, limiting dilution to ~4.97% (max 2.51m shares). Winners are Fenja Capital (high-yield lender with conversion optionality) and Curasight’s near-term liquidity; marginal losers are existing equity holders facing an effective ~5% cap on dilution plus a high-cost financing burden (5% setup fee ≈ DKK 1.25m + ~15% p.a. drawn interest). Cross-asset impact is muted — negligible corporate bond flow, slight uptick in equity volatility and put demand for CURAS; FX/commodities irrelevant.

Risk assessment: Tail risks include clinical trial setbacks or a failure to draw the second tranche (Q2 2026) forcing a fresh equity raise at a lower price, and adverse conversion mechanics if the directed-issue subscription price is depressed; both could exceed 20% downside. Short-term (days-weeks) risks center on directed-issue pricing and market reaction; medium-term (Q2 2026) hinges on the optional tranche draw decision; long-term (>12 months) depends on uTRACE/uTREAT clinical milestones and commercialization. Hidden dependency: conversion price is tied to the directed issue (125% of that price), so outcome depends on an external equity placement price rather than a fixed market metric.

Trade implications: Direct play — small-cap, high-risk short of CURAS (ticker CURAS) or buying 3–6 month puts is logical given expensive debt and limited dilution (sell-the-news on directed issue). Relative trade — rotate from CURAS-sized positions into cash-rich Nordic biotechs (e.g., long GEN 1–2% NAV or NVO 1–2% NAV) for better risk-adjusted exposure. Options — consider 3–6 month put spreads on CURAS to cap cost or buy protective puts if long.

Contrarian angles: Consensus will treat this as routine bridge financing; missing point is the financing cost (~5% setup + ~15% p.a. drawn interest) materially shortens runway economics and raises probability of follow-on equity within 12 months if milestones slip. Market may underprice the optionality risk tied to the Q2 2026 tranche and directed-issue linkage; if directed issue pricing is strong, conversion economics could actually be shareholder-friendly (limited dilution at a premium), creating a quick mean-reversion trade.

Key Decisions for Investors

• Establish a tactical 0.5–1.0% NAV short position in CURAS (ticker CURAS) or buy 3–6 month put spreads targeting ~10–20% downside; initiate within 5 trading days before directed-issue pricing and close if the share falls >20% or if conversion price announced > current market +5%.
• If reducing small-cap biotech exposure, redeploy 1–2% NAV into larger Nordic biopharma: long Genmab (GEN) or Novo Nordisk (NVO) for 3–12 months to capture defensive industry tailwinds and lower financing risk.
• If convertible arbitrage-capable and directed-issue subscription price is published, evaluate buy-the-stock + short-convert hedge only if conversion price < current market; target basis capture of 3–6% and exit within 30 days of conversion or on conversion-price announcement.
• Monitor three specific triggers and act: (A) directed-issue subscription price announcement (expected within 5 trading days) — if conversion price implies >5% dilution at a >10% premium, cover shorts; (B) Q2 2026 decision to draw the second DKK 15m tranche — treat non-draw as bearish; (C) any uTRACE/uTREAT clinical updates — positive readouts justify re-risking within 1–3 months.